Filing Flows › 8-K events › Valion Bio
Valion Bio: departure or appointment of directors and officers
Form 8-K filed Nov 5, 2026 · items 5.02
What the filing says
On October 31, 2026, Lisa Wolf notified the Special Committee of the Board of Directors of Valion Bio, Inc. (the “Company”) of her decision to voluntarily resign from her positions as President, Chief Operating Officer and Chief Financial Officer of the Company. Wolf’s resignation from each of these positions will beco
Read the filing on SEC EDGAR →
What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →
What this kind of filing means
Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.
Valion Bio’s other material 8-Ks
- Nov 2, 2026 — FDA decisions NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome
- Oct 29, 2026 — FDA decisions Valion Bio Announces Positive Safety Results from U.S. Government-Funded Entolimod Study, Paving Way
- Oct 27, 2026 — Share offerings
- Oct 26, 2026 — FDA decisions Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
Other recent cfo changes
- Karbon-X Nov 6, 2026
- Power Solutions International Nov 6, 2026
- Audax Private Credit Fund, LLC Nov 6, 2026
- Audax Credit BDC Nov 6, 2026
- Blaize Holdings Nov 5, 2026
- Digital Turbine Nov 5, 2026
- TransUnion Nov 5, 2026
- Teads Holding Nov 5, 2026
- Novelis Nov 5, 2026
- TripAdvisor Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.